JP7754506B2 - ポリオウイルス受容体（ｐｖｒ）に対する抗体およびその使用 - Google Patents

ポリオウイルス受容体（ｐｖｒ）に対する抗体およびその使用

Info

Publication number
JP7754506B2
JP7754506B2 JP2022518775A JP2022518775A JP7754506B2 JP 7754506 B2 JP7754506 B2 JP 7754506B2 JP 2022518775 A JP2022518775 A JP 2022518775A JP 2022518775 A JP2022518775 A JP 2022518775A JP 7754506 B2 JP7754506 B2 JP 7754506B2
Authority
JP
Japan
Prior art keywords
seq
set forth
amino acid
antibody
chain variable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2022518775A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022553129A (ja
JPWO2021070181A5 (enExample
Inventor
アルベルト，フィリップ
ジェシャ，アリフ
フランソン，ヨハン
ジャメイアン，ヤザン
ヒューム，ジョアン
ツッカーマン，ピンカス
Original Assignee
ネクチン セラピューティクス エルティーディー．
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ネクチン セラピューティクス エルティーディー． filed Critical ネクチン セラピューティクス エルティーディー．
Publication of JP2022553129A publication Critical patent/JP2022553129A/ja
Publication of JPWO2021070181A5 publication Critical patent/JPWO2021070181A5/ja
Priority to JP2025069830A priority Critical patent/JP2025118688A/ja
Application granted granted Critical
Publication of JP7754506B2 publication Critical patent/JP7754506B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0681—Cells of the genital tract; Non-germinal cells from gonads
    • C12N5/0682—Cells of the female genital tract, e.g. endometrium; Non-germinal cells from ovaries, e.g. ovarian follicle cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Communicable Diseases (AREA)
  • Hematology (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Cell Biology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Microbiology (AREA)
  • Reproductive Health (AREA)
  • General Engineering & Computer Science (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
JP2022518775A 2019-10-08 2020-10-07 ポリオウイルス受容体（ｐｖｒ）に対する抗体およびその使用 Active JP7754506B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2025069830A JP2025118688A (ja) 2019-10-08 2025-04-21 ポリオウイルス受容体（ｐｖｒ）に対する抗体およびその使用

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962912534P 2019-10-08 2019-10-08
US62/912,534 2019-10-08
PCT/IL2020/051082 WO2021070181A1 (en) 2019-10-08 2020-10-07 Antibodies against the poliovirus receptor (pvr) and uses thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2025069830A Division JP2025118688A (ja) 2019-10-08 2025-04-21 ポリオウイルス受容体（ｐｖｒ）に対する抗体およびその使用

Publications (3)

Publication Number Publication Date
JP2022553129A JP2022553129A (ja) 2022-12-22
JPWO2021070181A5 JPWO2021070181A5 (enExample) 2023-10-17
JP7754506B2 true JP7754506B2 (ja) 2025-10-15

Family

ID=73038283

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2022518775A Active JP7754506B2 (ja) 2019-10-08 2020-10-07 ポリオウイルス受容体（ｐｖｒ）に対する抗体およびその使用
JP2025069830A Pending JP2025118688A (ja) 2019-10-08 2025-04-21 ポリオウイルス受容体（ｐｖｒ）に対する抗体およびその使用

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2025069830A Pending JP2025118688A (ja) 2019-10-08 2025-04-21 ポリオウイルス受容体（ｐｖｒ）に対する抗体およびその使用

Country Status (11)

Country Link
US (1) US20220372161A1 (enExample)
EP (1) EP4041392A1 (enExample)
JP (2) JP7754506B2 (enExample)
KR (1) KR20220082007A (enExample)
CN (2) CN114502595B (enExample)
AU (1) AU2020363041B2 (enExample)
BR (1) BR112022006620A2 (enExample)
CA (1) CA3156983A1 (enExample)
IL (1) IL291540A (enExample)
MX (1) MX2022004194A (enExample)
WO (1) WO2021070181A1 (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2024011278A (es) 2022-03-15 2024-09-25 Compugen Ltd Anticuerpos antagonistas de il-18bp y su uso en monoterapia y terapia de combinacion en el tratamiento del cancer.
KR102615797B1 (ko) * 2022-04-28 2023-12-19 가톨릭대학교 산학협력단 T 세포에 의한 교모세포종 치료 효과의 유효성 예측 방법
AU2023331612A1 (en) 2022-09-04 2025-02-13 Nectin Therapeutics Ltd. Drug conjugates of humanized anti pvr antibodies
TW202515608A (zh) 2023-06-26 2025-04-16 以色列商坎布根有限公司 Ｉｌ—１８ｂｐ拮抗抗體及其於癌症治療之單一療法及組合療法的用途

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2014198710A (ja) 2013-03-13 2014-10-23 国立大学法人 筑波大学 免疫疾患に対する医薬組成物
JP2015134764A (ja) 2015-01-26 2015-07-27 国立大学法人 筑波大学 可溶型ｃｄ１５５タンパク質を用いた癌の検出方法
JP2018531914A (ja) 2015-09-14 2018-11-01 コンパス セラピューティクス リミテッド ライアビリティ カンパニー ＣＤ１５５／ＴＩＧＩＴ経路およびＴＧＦ−βのアンタゴニストを介してがんを処置するための組成物および方法
JP2019511212A (ja) 2016-03-01 2019-04-25 イサム リサーチ ディベロップメント カンパニー オブ ザ ヘブルー ユニバーシティ オブ エルサレム エルティーディー． ヒトポリオウイルス受容体（ｐｖｒ）に特異的な抗体

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL85035A0 (en) 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
EP0307434B2 (en) 1987-03-18 1998-07-29 Scotgen Biopharmaceuticals, Inc. Altered antibodies
DE122004000008I1 (de) 1991-06-14 2005-06-09 Genentech Inc Humanisierter Heregulin Antikörper.
EP0714409A1 (en) 1993-06-16 1996-06-05 Celltech Therapeutics Limited Antibodies
KR101155191B1 (ko) 1999-01-15 2012-06-13 제넨테크, 인크. 효과기 기능이 변화된 폴리펩티드 변이체
US7361740B2 (en) 2002-10-15 2008-04-22 Pdl Biopharma, Inc. Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis
EP1481993A1 (en) * 2003-05-28 2004-12-01 Xerion Pharmaceuticals AG Modulation of the poliovirus receptor function
SG10202006538TA (en) * 2014-12-23 2020-08-28 Bristol Myers Squibb Co Antibodies to tigit

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2014198710A (ja) 2013-03-13 2014-10-23 国立大学法人 筑波大学 免疫疾患に対する医薬組成物
JP2015134764A (ja) 2015-01-26 2015-07-27 国立大学法人 筑波大学 可溶型ｃｄ１５５タンパク質を用いた癌の検出方法
JP2018531914A (ja) 2015-09-14 2018-11-01 コンパス セラピューティクス リミテッド ライアビリティ カンパニー ＣＤ１５５／ＴＩＧＩＴ経路およびＴＧＦ−βのアンタゴニストを介してがんを処置するための組成物および方法
JP2019511212A (ja) 2016-03-01 2019-04-25 イサム リサーチ ディベロップメント カンパニー オブ ザ ヘブルー ユニバーシティ オブ エルサレム エルティーディー． ヒトポリオウイルス受容体（ｐｖｒ）に特異的な抗体

Also Published As

Publication number Publication date
BR112022006620A2 (pt) 2022-08-30
KR20220082007A (ko) 2022-06-16
EP4041392A1 (en) 2022-08-17
JP2022553129A (ja) 2022-12-22
AU2020363041B2 (en) 2025-11-06
WO2021070181A1 (en) 2021-04-15
CN114502595A (zh) 2022-05-13
US20220372161A1 (en) 2022-11-24
CA3156983A1 (en) 2021-04-15
IL291540A (en) 2022-05-01
CN114502595B (zh) 2025-05-23
MX2022004194A (es) 2022-05-02
CN120424218A (zh) 2025-08-05
AU2020363041A1 (en) 2022-04-14
JP2025118688A (ja) 2025-08-13

Similar Documents

Publication Publication Date Title
JP7366908B2 (ja) Ｐｄ－１に対する単一ドメイン抗体及びその変異体
JP7274426B2 (ja) 抗ｇｉｔｒアゴニスト抗体での癌の処置
JP2020508334A (ja) Ｃｄ１３７及び腫瘍抗原に結合できる二重特異性結合分子並びにその使用
JP7754506B2 (ja) ポリオウイルス受容体（ｐｖｒ）に対する抗体およびその使用
JP2019516394A (ja) 新規抗ｐｄ−ｌ１抗体
KR20180081606A (ko) 암 치료에서의 단독의, 또는 면역 자극제와 병용한, fgfr2 억제제
CA3120059A1 (en) Anti-periostin antibodies and uses thereof
CN114364400A (zh) 使用pd-1轴抑制剂及抗骨膜蛋白抗体治疗癌症的方法
US20240270840A1 (en) Antibodies against cd112r and uses thereof
WO2020128638A1 (en) Flt3 agonist antibodies and uses thereof
JP2025504529A (ja) がんの治療のための併用療法
EA045980B1 (ru) Антитела против рецептора полиовируса (pvr) и их применение
US20240052065A1 (en) Binding molecules for the treatment of cancer
HK40073145A (en) Antibodies against the poliovirus receptor (pvr) and uses thereof
TW202434631A (zh) 抗il-2抗體之使用方法
EP4185388A1 (en) A combination of anti-dr5 antibodies and an immunomodulatory imide drug for use in treating multiple myeloma
CN113368232A (zh) 多特异性抗原结合蛋白及其应用
HK1260737A1 (en) Novel anti-pd-l1 antibodies
HK1260737B (en) Novel anti-pd-l1 antibodies

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220404

RD12 Notification of acceptance of power of sub attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7432

Effective date: 20221118

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20221118

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20231006

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20231006

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20231201

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20240926

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20241002

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20241106

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20250106

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250421

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250428

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250618

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250829

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20250918

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20250925

R150 Certificate of patent or registration of utility model

Ref document number: 7754506

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150